The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 15, 2020
Filed:
Jul. 05, 2018
Applicant:
Industry-university Cooperation Foundation Hanyang University, Seoul, KR;
Inventors:
Chae Ok Yun, Seoul, KR;
Won Jai Lee, Seoul, KR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 48/00 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 39/235 (2006.01); A61P 17/02 (2006.01); C12N 15/861 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 39/00 (2013.01); A61K 39/235 (2013.01); A61K 39/395 (2013.01); A61K 48/00 (2013.01); A61P 17/02 (2018.01); C12N 15/113 (2013.01); C12N 15/861 (2013.01); G01N 33/50 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/531 (2013.01);
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating a keloid disease or scars. The inventors of the present invention discovered that mortalin expression inhibition and the interaction between mortalin and p53 may be new targets for keloid treatment. In the present invention, apoptosis and an anti-fibrotic effect were verified by preparing a mortalin-specific shRNA (dE1-RGD/GFP/shMOT) and injecting same in a keloid spheroid. Thus, by reducing ECM expression and inducing apoptosis in a keloid spheroid, mortalin knockdown may be very usefully employed for keloid treatment.